Teva acquires part of Merck KGaA women's health division
Teva Pharmaceutical Industries Ltd., an Israel-based maker of generic drugs with local operations, said it has completed the acquisition of Théramex, which was part of Merck KGaA's European-based women's health business, for an undisclosed price.
Teva Pharmaceutical Industries Ltd., an Israel-based maker of generic drugs with local operations, said it has completed the acquisition of Théramex, which was part of Merck KGaA's European-based women's health business, for an undisclosed price.
The price was not disclosed.
Théramex, which has more than 300 employees, has a broad portfolio of women's health and gynecology products, sold in more than 50 countries. In partnership with Merck & Co., a separate operation from the European company, it is developing an oral contraceptive based on natural estrogens that is awaiting approval in Europe.
With 2009 net sales of $13.9 billion, Teva employs more than 40,000 people around the world.
Teva Pharmaceuticals USA, headquartered in North Wales, Montgomery County, announced in October it will build a $295 million distribution facility in the Bustleton section of Philadelphia, where it expects to employ 500 people in the next five years.
Its stock was trading on the Nasdaq market at $52.09 a share, down 43 cents from Tuesday's close.
- Diane Mastrull